Progressive Parkinsonism by acute dysfunction of excitatory amino acid transporters in the rat substantia nigra

Neurobiology of Disease

Volumn 65, Issue , 2014, Pages 69-81

  Assous, Maxime ^a   Had Aissouni, Laurence ^a   Gubellini, Paolo ^a   Melon, Christophe ^a   Nafia, Imane ^b   Salin, Pascal ^a   Kerkerian Le Goff, Lydia ^a   Kachidian, Philippe ^a  

^a AIX MARSEILLE UNIVERSITÉ   (France)

^b Fluofarma   (France)

Author keywords

Animal model; Excitotoxicity; Glutamate transporters; Neurodegeneration; Neuroprotection; Oxidative stress; Parkinson's disease; PDC (l trans pyrrolidine 2,4 dicarboxylate)

Indexed keywords

2,4 PYRROLIDINEDICARBOXYLIC ACID; ACETYLCYSTEINE; EXCITATORY AMINO ACID TRANSPORTER; GLUTATHIONE; IFENPRODIL; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ELECTROPHYSIOLOGY; CELL DEATH; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; EXCITOTOXICITY; MALE; NERVE FIBER DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSONISM; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; RAT; SUBSTANTIA NIGRA;

ANIMAL MODEL; EXCITOTOXICITY; GLUTAMATE TRANSPORTERS; NEURODEGENERATION; NEUROPROTECTION; OXIDATIVE STRESS; PARKINSON'S DISEASE; PDC (L-TRANS-PYRROLIDINE-2,4-DICARBOXYLATE);

ACETYLCYSTEINE; ACTION POTENTIALS; ANIMALS; DICARBOXYLIC ACIDS; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; FORELIMB; FREE RADICAL SCAVENGERS; FUNCTIONAL LATERALITY; GLUTAMATE DECARBOXYLASE; GLUTAMATE PLASMA MEMBRANE TRANSPORT PROTEINS; MALE; MOTOR ACTIVITY; NEUROGLIA; NEUROTRANSMITTER UPTAKE INHIBITORS; PARKINSONIAN DISORDERS; PYRROLIDINES; RATS; RATS, WISTAR; SUBSTANTIA NIGRA; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TYROSINE 3-MONOOXYGENASE;

EID: 84896735312     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.01.011     Document Type: Article

References (68)

1. Ahmed I., Liang Y., Schools S., Dawson V.L., Dawson T.M., Savitt J.M. Development and characterization of a new Parkinson's disease model resulting from impaired autophagy. J. Neurosci. 2012, 32:16503-16509.
2. Aoyama K., Suh S.W., Hamby A.M., Liu J., Chan W.Y., Chen Y., Swanson R.A. Neuronal glutathione deficiency and age-dependent neurodegeneration in the EAAC1 deficient mouse. Nat. Neurosci. 2006, 9:119-126.
3. Aoyama K., Matsumura N., Watabe M., Nakaki T. Oxidative stress on EAAC1 is involved in MPTP-induced glutathione depletion and motor dysfunction. Eur. J. Neurosci. 2008, 27:20-30.
4. Baron A., Montagne A., Casse F., Launay S., Maubert E., Ali C., Vivien D. NR2D-containing NMDA receptors mediate tissue plasminogen activator-promoted neuronal excitotoxicity. Cell Death Differ. 2010, 17:860-871.
5. Berman A.E., Chan W.Y., Brennan A.M., Reyes R.C., Adler B.L., Suh S.W., Kauppinen T.M., Edling Y., Swanson R.A. N-acetylcysteine prevents loss of dopaminergic neurons in the EAAC1-/- mouse. Ann. Neurol. 2011, 69:509-520.
6. Biju G., De la Fuente-Fernandez R. Dopaminergic function and progression of Parkinson's disease: PET findings. Parkinsonism Relat. Disord. 2009, 15(Suppl. 4):S38-S40.
7. Blandini F., Porter R.H., Greenamyre J.T. Glutamate and Parkinson's disease. Mol. Neurobiol. 1996, 12:73-94.
8. Blesa J., Juri C., Garcia-Cabezas M.A., Adanez R., Sanchez-Gonzalez M.A., Cavada C., Obeso J.A. Inter-hemispheric asymmetry of nigrostriatal dopaminergic lesion: a possible compensatory mechanism in Parkinson's disease. Front. Syst. Neurosci. 2011, 5:92-.
9. Brothwell S.L., Barber J.L., Monaghan D.T., Jane D.E., Gibb A.J., Jones S. NR2B- and NR2D-containing synaptic NMDA receptors in developing rat substantia nigra pars compacta dopaminergic neurones. J. Physiol. 2008, 586:739-750.
10. Carlsson M., Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease. Trends Neurosci. 1990, 13:272-276.
11. Cheramy A., Chesselet M.F., Romo R., Leviel V., Glowinski J. Effects of unilateral electrical stimulation of various thalamic nuclei on the release of dopamine from dendrites and nerve terminals of neurons of the two nigrostriatal dopaminergic pathways. Neuroscience 1983, 8:767-780.
12. Cheramy A., Romo R., Godeheu G., Glowinski J. Effects of electrical stimulation of various midline thalamic nuclei on the bilateral release of dopamine from dendrites and nerve terminals of neurons in the nigro-striatal dopaminergic pathways. Neurosci. Lett. 1984, 44:193-198.
13. Chesselet M.F., Richter F., Zhu C., Magen I., Watson M.B., Subramaniam S.R. A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice. Neurotherapeutics 2012, 9:297-314.
14. Cheung Z.H., Ip N.Y. The emerging role of autophagy in Parkinson's disease. Mol. Brain 2009, 2:29.
15. Chinta S.J., Kumar M.J., Hsu M., Rajagopalan S., Kaur D., Rane A., Nicholls D.G., Choi J., Andersen J.K. Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration. J. Neurosci. 2007, 27:13997-14006.
16. Damier P., Hirsch E.C., Agid Y., Graybiel A.M. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999, 122(Pt 8):1437-1448.
17. Danbolt N.C. Glutamate uptake. Prog. Neurobiol. 2001, 65:1-105.
18. Dawson T.M., Ko H.S., Dawson V.L. Genetic animal models of Parkinson's disease. Neuron 2010, 66:646-661.
19. De Groot J. The Rat Forebrain in Stereotaxic Coordinates 1959.
20. Dexter D.T., Carter C.J., Wells F.R., Javoy-Agid F., Agid Y., Lees A., Jenner P., Marsden C.D. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 1989, 52:381-389.
21. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991, 114(Pt 5):2283-2301.
22. Garrido M., Tereshchenko Y., Zhevtsova Z., Taschenberger G., Bahr M., Kugler S. Glutathione depletion and overproduction both initiate degeneration of nigral dopaminergic neurons. Acta Neuropathol. 2011, 121:475-485.
23. Glowinski J., Niecoullon A., Cheramy A. Regulations of the activity of the nigrostriatal dopaminergic pathways by cortical, cerebellar, and sensory neuronal afferences. Adv. Biochem. Psychopharmacol. 1978, 19:75-87.
24. Goemaere J., Knoops B. Peroxiredoxin distribution in the mouse brain with emphasis on neuronal populations affected in neurodegenerative disorders. J. Comp. Neurol. 2012, 520:258-280.
25. Had-Aissouni L. Toward a new role for plasma membrane sodium-dependent glutamate transporters of astrocytes: maintenance of antioxidant defenses beyond extracellular glutamate clearance. Amino Acids 2012, 42:181-197.
26. Hardingham G.E., Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat. Rev. Neurosci. 2010, 11:682-696.
27. Hayes D., Wiessner M., Rauen T., McBean G.J. Transport of l-[14C]cystine and l-[14C]cysteine by subtypes of high affinity glutamate transporters over-expressed in HEK cells. Neurochem. Int. 2005, 46:585-594.
28. Jackson-Lewis V., Blesa J., Przedborski S. Animal models of Parkinson's disease. Parkinsonism Relat. Disord. 2012, 18(Suppl. 1):S183-S185.
29. Jenner P., Dexter D.T., Sian J., Schapira A.H., Marsden C.D. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group. Ann. Neurol. 1992, 32:S82-S87. (Suppl.).
30. Johnson K.A., Conn P.J., Niswender C.M. Glutamate receptors as therapeutic targets for Parkinson's disease. CNS. Neurol. Disord. Drug Targets. 2009, 8:475-491.
31. Jones S., Gibb A.J. Functional NR2B- and NR2D-containing NMDA receptor channels in rat substantia nigra dopaminergic neurones. J. Physiol. 2005, 569:209-221.
32. Kohl B.K., Dannhardt G. The NMDA receptor complex: a promising target for novel antiepileptic strategies. Curr. Med. Chem. 2001, 8:1275-1289.
33. Lieu C.A., Subramanian T. The interhemispheric connections of the striatum: implications for Parkinson's disease and drug-induced dyskinesias. Brain Res. Bull. 2012, 87:1-9.
34. Liu Y., Wong T.P., Aarts M., Rooyakkers A., Liu L., Lai T.W., Wu D.C., Lu J., Tymianski M., Craig A.M., Wang Y.T. NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J. Neurosci. 2007, 27:2846-2857.
35. Magen I., Chesselet M.F. Genetic mouse models of Parkinson's disease. The state of the art. Prog. Brain Res. 2010, 184:53-87.
36. Martel M.A., Ryan T.J., Bell K.F., Fowler J.H., McMahon A., Al-Mubarak B., Komiyama N.H., Horsburgh K., Kind P.C., Grant S.G., Wyllie D.J., Hardingham G.E. The subtype of GluN2 C-terminal domain determines the response to excitotoxic insults. Neuron 2012, 74:543-556.
37. Martinez T.N., Greenamyre J.T. Toxin models of mitochondrial dysfunction in Parkinson's disease. Antioxid. Redox Signal. 2012, 16:920-934.
38. Massieu L., Morales-Villagran A., Tapia R. Accumulation of extracellular glutamate by inhibition of its uptake is not sufficient for inducing neuronal damage: an in vivo microdialysis study. J. Neurochem. 1995, 64:2262-2272.
39. McGeer P.L., McGeer E.G. Glial reactions in Parkinson's disease. Mov. Disord. 2008, 23:474-483.
40. McNaught K.S., Jenner P. Extracellular accumulation of nitric oxide, hydrogen peroxide, and glutamate in astrocytic cultures following glutathione depletion, complex I inhibition, and/or lipopolysaccharide-induced activation. Biochem. Pharmacol. 2000, 60:979-988.
41. Montiel T., Camacho A., Estrada-Sanchez A.M., Massieu L. Differential effects of the substrate inhibitor l-trans-pyrrolidine-2,4-dicarboxylate (PDC) and the non-substrate inhibitor dl-threo-beta-benzyloxyaspartate (dl-TBOA) of glutamate transporters on neuronal damage and extracellular amino acid levels in rat brain in vivo. Neuroscience 2005, 133:667-678.
42. Nafia I., Re D.B., Masmejean F., Melon C., Kachidian P., Kerkerian-Le G.L., Nieoullon A., Had-Aissouni L. Preferential vulnerability of mesencephalic dopamine neurons to glutamate transporter dysfunction. J. Neurochem. 2008, 105:484-496.
43. Nieoullon A., Cheramy A., Glowinski J. Interdependence of the nigrostriatal dopaminergic systems on the two sides of the brain in the cat. Science 1977, 198:416-418.
44. Olanow C.W. The pathogenesis of cell death in Parkinson's disease-2007. Mov. Disord. 2007, 22(Suppl. 17):S335-S342.
45. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1998.
46. Pearce R.K., Owen A., Daniel S., Jenner P., Marsden C.D. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J. Neural Transm. 1997, 104:661-677.
47. Perry T.L., Godin D.V., Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency?. Neurosci. Lett. 1982, 33:305-310.
48. Plaitakis A., Shashidharan P. Glutamate transport and metabolism in dopaminergic neurons of substantia nigra: implications for the pathogenesis of Parkinson's disease. J. Neurol. 2000, 247(Suppl. 2):II25-II35.
49. Price D.L., Rockenstein E., Ubhi K., Phung V., Lean-Lewis N., Askay D., Cartier A., Spencer B., Patrick C., Desplats P., Ellisman M.H., Masliah E. Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy-implications for excitotoxicity. PLoS One 2010, 5:e14020-.
50. Prybylowski K., Chang K., Sans N., Kan L., Vicini S., Wenthold R.J. The synaptic localization of NR2B-containing NMDA receptors is controlled by interactions with PDZ proteins and AP-2. Neuron 2005, 47:845-857.
51. Rappold P.M., Tieu K. Astrocytes and therapeutics for Parkinson's disease. Neurotherapeutics 2010, 7:413-423.
52. Richard M.J., Portal B., Meo J., Coudray C., Hadjian A., Favier A. Malondialdehyde kit evaluated for determining plasma and lipoprotein fractions that react with thiobarbituric acid. Clin. Chem. 1992, 38:704-709.
53. Rodriguez M.C., Obeso J.A., Olanow C.W. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann. Neurol. 1998, 44:S175-S188.
54. Roedter A., Winkler C., Samii M., Walter G.F., Brandis A., Nikkhah G. Comparison of unilateral and bilateral intrastriatal 6-hydroxydopamine-induced axon terminal lesions: evidence for interhemispheric functional coupling of the two nigrostriatal pathways. J. Comp. Neurol. 2001, 432:217-229.
55. Rousseaux M.W., Marcogliese P.C., Qu D., Hewitt S.J., Seang S., Kim R.H., Slack R.S., Schlossmacher M.G., Lagace D.C., Mak T.W., Park D.S. Progressive dopaminergic cell loss with unilateral-to-bilateral progression in a genetic model of Parkinson disease. Proc Natl Acad Sci USA 2012, 109:15918-15923.
56. Schapira A.H., Jenner P. Etiology and pathogenesis of Parkinson's disease. Mov. Disord. 2011, 26:1049-1055.
57. Schulz J.B., Lindenau J., Seyfried J., Dichgans J. Glutathione, oxidative stress and neurodegeneration. Eur. J. Biochem. 2000, 267:4904-4911.
58. Seelig G.F., Meister A. Glutathione biosynthesis; gamma-glutamylcysteine synthetase from rat kidney. Methods Enzymol. 1985, 113:379-390.
59. Seutin V., Engel D. Differences in Na+ conductance density and Na+ channel functional properties between dopamine and GABA neurons of the rat substantia nigra. J. Neurophysiol. 2010, 103:3099-3114.
60. Shashidharan P., Huntley G.W., Murray J.M., Buku A., Moran T., Walsh M.J., Morrison J.H., Plaitakis A. Immunohistochemical localization of the neuron-specific glutamate transporter EAAC1 (EAAT3) in rat brain and spinal cord revealed by a novel monoclonal antibody. Brain Res. 1997, 773:139-148.
61. Sian J., Dexter D.T., Lees A.J., Daniel S., Agid Y., Javoy-Agid F., Jenner P., Marsden C.D. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 1994, 36:348-355.
62. Sian J., Dexter D.T., Lees A.J., Daniel S., Jenner P., Marsden C.D. Glutathione-related enzymes in brain in Parkinson's disease. Ann. Neurol. 1994, 36:356-361.
63. Suarez F., Zhao Q., Monaghan D.T., Jane D.E., Jones S., Gibb A.J. Functional heterogeneity of NMDA receptors in rat substantia nigra pars compacta and reticulata neurones. Eur. J. Neurosci. 2010, 32:359-367.
64. Surmeier D.J., Guzman J.N., Sanchez-Padilla J., Schumacker P.T. The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease. Neuroscience 2011, 198:221-231.
65. Tilleux S., Hermans E. Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. J. Neurosci. Res. 2007, 85:2059-2070.
66. Trotti D., Rossi D., Gjesdal O., Levy L.M., Racagni G., Danbolt N.C., Volterra A. Peroxynitrite inhibits glutamate transporter subtypes. J. Biol. Chem. 1996, 271:5976-5979.
67. Vila M., Jackson-Lewis V., Guegan C., Wu D.C., Teismann P., Choi D.K., Tieu K., Przedborski S. The role of glial cells in Parkinson's disease. Curr. Opin. Neurol. 2001, 14:483-489.
68. Yacoubian T.A., Standaert D.G. Targets for neuroprotection in Parkinson's disease. Biochim. Biophys. Acta 2009, 1792:676-687.